Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

Sanofi (ENXTPA:SAN) recently received orphan drug designation from Japan's Ministry of Health for riliprubart, aimed at treating chronic inflammatory demyelinating polyneuropathy. This underscores the ...

(NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase). The agency ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small ...

One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy. Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...